Heart Failure Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working | Amgen, AstraZeneca, Merck Sharp & Dohme Corp, Bayer

Heart Failure Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working | Amgen, AstraZeneca, Merck Sharp & Dohme Corp, Bayer
Heart Failure Market
Heart Failure Market Emerging therapies such as Empagliflozin, Vericiguat, AZD4831, Dapagliflozin, Omecamtiv mecarbil, and others are expected to boost the heart failure market in the upcoming years.

DelveInsight has launched a new report on “Heart Failure – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Heart Failure, historical and forecasted epidemiology as well as the Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Breakthroughs in the Heart Failure Market:

  • The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. 
  • In February 2014, Mesoblast, Inc. commenced a study called “Dream HF-1,” a Phase III trial that was double-blind, randomized, and controlled by a sham procedure. The trial aimed to assess the effectiveness and safety of Allogeneic Mesenchymal Precursor Cells (known as Rexlemestrocel-L) in managing chronic heart failure due to LV Systolic Dysfunction, whether of ischemic or nonischemic origin. The primary goals were to measure Revascor’s capability to reduce recurring non-fatal heart failure-related major adverse cardiac events (HF-MACE) in patients with left ventricular dysfunction. Additionally, it sought to delay or prevent disease advancement to end-stage HF and terminal cardiac events, which encompassed death, left ventricular assist device (LVAD) implantation, or cardiac transplant. By April 2017, the trial had reached a successful pre-planned interim assessment for effectiveness in the initial 270 participants. An independent data monitoring committee formally recommended continuing the trial following this positive evaluation.

Some of the key facts of the Heart Failure Market Report:

  • Among 7MM, the US reported the highest number of prevalent cases.
  • As per the DelveInsight analysis, the total prevalent cases of Heart Failure in Italy was found to be ~1,472,000 cases.

Key benefits of the Heart Failure Market report:

  1. Heart Failure market report covers a descriptive overview and comprehensive insight of the Heart Failure Epidemiology and Heart Failure  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Heart Failure market report provides insights on the current and emerging therapies.
  3. Heart Failure market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Heart Failure market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Heart Failure market.

Got queries? Click here to know more about the Heart Failure Market Landscape.

Heart Failure Overview

Heart failure is a chronic medical condition where the heart is unable to pump blood efficiently to meet the body’s needs. This doesn’t necessarily mean that the heart has stopped functioning, but rather that it’s not working as well as it should. It’s a progressive condition that can affect either side of the heart and can be classified as systolic heart failure (when the heart can’t pump enough blood) or diastolic heart failure (when the heart has trouble relaxing and filling with blood).

Symptoms of heart failure can include:

Shortness of Breath: Difficulty breathing, especially during physical activity or when lying down.

Fatigue and Weakness: Feeling tired and weak, even with minimal physical exertion.

Swelling: Swelling in the legs, ankles, feet, or abdomen caused by fluid buildup (edema).

Rapid or Irregular Heartbeat: Palpitations or irregular heart rhythms might occur.

Persistent Cough or Wheezing: A cough that produces white or pink blood-tinged phlegm might indicate fluid buildup in the lungs.

Reduced Ability to Exercise: Feeling less capable of performing physical activities compared to before.

Several factors can contribute to heart failure, including coronary artery disease, high blood pressure, heart valve disorders, cardiomyopathy (disease of the heart muscle), congenital heart defects, infections, and other health conditions.

Management of heart failure involves a combination of lifestyle changes, medications, and in some cases, surgical interventions or medical devices to assist heart function. Treatment aims to improve symptoms, slow the progression of the condition, and prevent complications. It’s crucial for individuals with heart failure to work closely with healthcare providers to develop a personalized treatment plan and monitor their condition regularly.

Heart Failure Market 

The dynamics of the Heart Failure market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Empagliflozin ((Boehringer Ingelheim/Eli Lilly and Company), Vericiguat (Merck Sharp & Dohme Corp/Bayer), AZD4831 (AstraZeneca), Dapagliflozin (AstraZeneca), Omecamtiv mecarbil (Amgen), and others during the forecasted period 2019-2032.

Heart Failure Pipeline Therapies and Key Companies 

  • Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
  • Vericiguat: Merck Sharp & Dohme Corp/Bayer
  • AZD4831: AstraZeneca
  • Dapagliflozin: AstraZeneca
  • Omecamtiv mecarbil: Amgen

Heart Failure Market Drivers 

  • Research and development strategies
  • Rising prevalence of the disease
  • Evidence-based therapies

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Heart Failure Patient Share (%) Overview at a Glance

5. Heart Failure Market Overview at a Glance

6. Heart Failure Disease Background and Overview

7. Heart Failure Epidemiology and Patient Population

8. Country-Specific Patient Population of Heart Failure 

9. Heart Failure Current Treatment and Medical Practices

10. Unmet Needs

11. Heart Failure Emerging Therapies

12. Heart Failure Market Outlook

13. Country-Wise Heart Failure Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Heart Failure Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Heart Failure Market Outlook 2032.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services